Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells
When previously cryproserved NK cells are still available, further re-infusions may be
performed, according to PI's evaluation. The number of remaining NK cells must be sufficient
for the reinfusion of at least the minimum dose of cells (106/kg). At least two months
should elapse between two consecutive infusion procedures.
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the feasibility of the selection and reinfusion of 5x10E6 haploidentical natural killer (NK) cells /Kg of body weight (target cell dose) in at least 40% of adult patients with active acute myeloblastic leukemia (AML) entering the study
every 6 months
Yes
Italy: Ethics Committee
NK TRIAL
NCT00799799
October 2005
December 2009
Name | Location |
---|